Bipolar Disorder | Access and Reimbursement | US | 2018

Numerous drugs across multiple drug classes are available and used as monotherapies and/or adjunctive therapies for the treatment of bipolar disorder (BPD). The treatment armamentarium for BPD is growing increasingly genericized in the United States, along with improved patient access to antiepileptic drugs, approval for atypical antipsychotics in the treatment of BPD, and eased restrictions on the prescribing of off-label atypical antipsychotics and antidepressants. At the same time, the expanding generics presence has given U.S. payers greater leverage to control drug treatment costs in BPD. Understanding the current and expected influence of clinical metrics and value-for-dollar on market access and medical practice are key for developers of new therapies for BPD.

Questions Answered

  • How do payer policies affect the prescribing of branded oral atypical antipsychotics (e.g., Sunovion’s Latuda, Lundbeck/Otsuka Pharmaceutical’s Rexulti, Allergan’s Vraylar) and antidepressants (e.g., Lundbeck/Takeda Pharmaceutical’s Trintellix, Allergan’s Viibryd) in this genericized market?
  • In this mature and highly generic treatment landscape, what actions can marketers of therapies used to treat BPD employ to attain successful market access and thus overall sales?
  • What are the preferred pharmacoeconomic models for payers when evaluating new BPD therapies and what type of pharmacoeconomic data do they find most compelling?
  • To which of their BPD patients do psychiatrists anticipate prescribing the emerging therapies ALKS-3831 (Alkermes), NRX-101 (NeuroRX), and rapastinel (Allergan)? How do payers expect to reimburse these therapies?

Product Description

Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.

Markets covered: United States.

Primary research:

  • Survey of 101 psychiatrists in the United States.
  • Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).

Key companies: Alkermes, Allergan, AstraZeneca, Lundbeck, NeuroRX, Otsuka Pharmaceutical, SumitomoDainippon Pharma, Sunovion, Takeda Pharmaceutical, and Valeant Pharmaceuticals.

Key drugs: ALKS-3831, aripiprazole (Abilify, generics), Latuda, lamotrigine (Lamictal, generics), lithium, NRX-101, quetiapine IR/XR (Seroquel IR/XR, generics), rapastinel, Rexulti, Trintellix, Viibryd, and Vraylar.

Content highlights:

  • Reimbursement and contracting.
  • Access and prescribing.
  • Special topics.
  • Opportunities and challenges for emerging therapies.
Login to access report

launch Related Market Assessment Reports